Enriched Infant Formulas

• US 20080057178A1
• Filed: 06/29/2007
• Published: 03/06/2008
• Est. Priority Date: 06/30/2006
• Status: Abandoned Application

• Current Assignee: Abbott Laboratories Incorporated
• Original Assignee: Abbott Laboratories Incorporated
• Inventors: Prieto, Pedro, Barranco, Alejandro, Dohnalek, Margaret, Valverde, Eduardo, Rueda, Ricardo, Ramirez, Maria, Vazquez, Enrique
• Application Number:
  US11/771,435
• Publication Number:
  US 20080057178A1
• Time in Patent Office: Days
• US Class Current: 426/656
• CPC Class Codes: A23L 33/40 Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula

Abstract

Disclosed are infant formulas comprising, on an as-fed basis (A) at least about 5 mg/L of gangliosides, (B) at least about 150 mg/L of phospholipids, (C) lactoferrin, and (D) at least about 70 mg/L of sialic acid, with at least about 2.5% by weight of the sialic acid as lipid-bound sialic acid. From about 50% to 100% by weight of each of the gangliosides, phospholipids, lactoferrin, and sialic acid is provided by an enriched whey protein concentrate, with the concentrate representing at least about 6.5 g/L of the formula on an as-fed basis. Also disclosed are methods of using the formula to reduce the risk of diarrhea infants, and to produce a gut microflora profile similar to that of breast-fed infants.

Claims

1. Infant formula comprising, on an as-fed basis:

(A) at least about 5 mg/L of gangliosides,

(B) at least about 150 mg/L of phospholipids,

(C) lactoferrin, and

(D) at least about 70 mg/L of sialic acid, with at least about 2.5% by weight of the sialic acid as lipid-bound sialic acid;

wherein from about 50% to 100% by weight of each of the gangliosides, phospholipids, lactoferrin, and sialic acid are provided by an enriched whey protein concentrate, said concentrate representing at least about 6.5 g/L of the formula on an as-fed basis.

2. An infant formula according to claim 1 wherein the lipid-bound sialic acid represents from about 2.7% to about 5% by weight of the total sialic acid.

3. An infant formula according to claim 1 comprising, on an as-fed basis, (A) from about 7 mg/L to about 50 mg/L of gangliosides, (B) from about 200 mg/L to about 600 mg/L of phospholipids, and (C) from about 90 mg/L to about 250 mg/L of sialic acid.

4. An infant formula according to claim 1 comprising, on an as-fed basis, from about 50 mg/L to about 2000 mg/L of lactoferrin, with at least about 6% by weight of the lactoferrin as native lactoferrin.

5. An infant formula according to claim 1 wherein the total phospholipid comprises at least 20% by weight of sphingomyelin.

6. An infant formula according to claim 5 wherein the phospholipid comprises sphingomyelin, phosphatidyl ethanolamine, phosphatidyl choline, phosphatidyl inositol, and phosphatidyl serine.

7. An infant formula according to claim 1 further comprising from about 0.05% to about 5% of a fructopolysaccharide.

8. An infant formula according to claim 1 wherein the formula contains less than about 0.5% free glycomacropeptides, on an as-fed basis.

9. An infant formula according to claim 1 wherein the infant formula is substantially free of phospholipids, egg phospholipids, and combinations thereof.

10. An infant formulas according to claim 1 wherein the infant formula comprises less than about 0.2% by weight of milk fat on an as-fed basis.

11. An infant formula according to claim 1 wherein the infant formula is a powder.

12. An infant formula according to claim 1 wherein the infant formula is a ready-to-feed liquid.

13. An infant formula according to claim 1 comprising, on an as-fed basis, from about 6.5 g/L to about 10.9 g/L enriched whey protein concentrate.

14. An infant formula according to claim 1, wherein from about 60% to about 90% by weight of each of the gangliosides, phospholipids, lactoferrin, and sialic acid are provided by the enriched whey protein concentrate, said concentrate representing at least about 6.5 g/L of the formula on an as-fed basis.

15. A method of reducing the risk of diarrhea in an infant, comprising

(I) preparing an infant formula comprising, on an as-fed basis:

(A) at least about 5 mg/L of gangliosides,

(B) at least about 150 mg/L of phospholipids,

(C) lactoferrin,

(D) at least about 70 mg/L of total sialic acid with at least about 2.5% by weight of the sialic acid as lipid-bound sialic acid;

wherein from about 50% to 100% by weight of each of the gangliosides, phospholipids, lactoferrin, and sialic acid are provided by an enriched whey protein concentrate, said concentrate representing at least about 6.5 g/L of the formula on an as-fed basis,

(II) administering or instructing a caregiver to administer the formula to an infant.

16. A method according to claim 15 wherein the formula is administered as a sole source of nutrition.

17. A meth according to claim 15, wherein the infant formula comprises, on an as-fed basis, from about 50 mg/L to about 2000 mg/L of lactoferrin, with at least about 6% by weight of the lactoferrin as native lactoferrin.

18. A method according to claim 15 wherein the lipid-bound sialic acid represents from about 2.7% to about 5% by weight of the total sialic acid.

19. A method according to claim 15, wherein the infant formula comprises, on an as-fed basis, (A) from about 7 mg/L to about 50 mg/L of gangliosides, (B) from about 200 mg/L to about 600 mg/L of phospholipids, and (C) from about 90 mg/L to about 250 mg/L of sialic acid.

20. A method according to claim 15 wherein the total phospholipid comprises at least 20% by weight of sphingomyelin.

21. A method according to claim 15 wherein the infant formula comprises less than about 0.2% by weight of milk fat on an as-fed basis.

22. A method according to claim 15 wherein the formula comprises less than 0.5% by weight of free glycomacropeptides on an as-fed basis.

23. A method according to claim 15, wherein the infant formula comprises, on an as-fed basis, from about 6.5 g/L to about 10.9 g/L of enriched whey protein concentrate.

24. A method according to claim 15, wherein from about 60% to about 90% by weight of each of the gangliosides, phospholipids, lactoferrin, and sialic acid are provided by the enriched whey protein concentrate, said concentrate representing at least about 6.5 g/L of the formula on an as-fed basis.

25. A method of producing a gut microflora profile similar to that of breast-fed infants, said method comprising

(I) preparing an infant formula comprising, on an as-fed basis:

(A) at least about 5 mg/L of gangliosides,

(B) at least about 150 mg/L of phospholipids,

(C) lactoferrin,

(D) at least about 70 mg/L of total sialic acid with at least about 2.5% by weight of the sialic acid as lipid-bound sialic acid;

wherein from about 50% to 100% by weight of each of the gangliosides, phospholipids, lactoferrin, and sialic acid are provided by an enriched whey protein concentrate, said concentrate representing at least about 6.5 g/L of the infant formula on an as-fed basis,

(II) administering or instructing a caregiver to administer the formula to an infant.

26. A method according to claim 25, wherein the formula comprises, on an as-fed basis, from about 50 mg/L to about 2000 mg/L of lactoferrin, with at least about 6% by weight of the lactoferrin as native lactoferrin.

27. A method according to claim 25, wherein the infant formula comprises, on an as-fed basis, from about 6.5 g/L to about 10.9 g/L of enriched whey protein concentrate.

28. A method according to claim 25, wherein from about 60% to about 90% by weight of each of the gangliosides, phospholipids, lactoferrin, and sialic acid are provided by the enriched whey protein concentrate, said concentrate representing at least about 6.5 g/L of the formula on an as-fed basis

29. A method according to claim 25 wherein from about 50% to 100% by weight of the combination of gangliosides, phospholipids, and sialic acid is from an enriched whey protein concentrate.

30. A method according to claim 25 wherein the lipid-bound sialic acid represents from about 2.7% to about 5% by weight of the total sialic acid.

31. A method according to claim 25, wherein the formula comprises, on an as-fed basis, (A) from about 7 mg/L to about 50 mg/L of gangliosides, (B) from about 200 mg/L to about 600 mg/L of phospholipids, and (C) from about 90 mg/L to about 250 mg/L of sialic acid.

32. A method according to claim 25 wherein the total phospholipid comprises at least 20% by weight of sphingomyelin.

33. A method according to claim 25, wherein the formula comprises less than about 0.2% by weight of milk fat on an as-fed basis.

34. A method according to claim 25 wherein the formula comprises less than 0.5% by weight of free glycomacropeptides on an as-fed basis.

35. A method according to claim 25, wherein the formula further comprises from about 0.05% to about 5% of a fructopolysaccharide.